Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Eastern Cooperative Oncology Group
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Imunon
Alliance for Clinical Trials in Oncology
Northwestern University